Search Results - "Dan Costa, S."

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial by Loibl, S., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Wiebringhaus, H., Kümmel, S., Warm, M., Paepke, S., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Clemens, M., Dan Costa, S., Gerber, B., Engels, K., Nekljudova, V., von Minckwitz, G., Untch, M.

“…The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic…”
Get full text

G-protein-coupled receptor GPR30 expression as a prognostic factor in breast cancer patients by Ignatov, T, Weissenborn, C, Dan Costa, S, Ortmann, O, Ignatov, A

“…Abstract only…”
Get full text

Maximized Reduction of Primary Breast Tumor Size Using Preoperative Chemotherapy With Doxorubicin and Docetaxel by VON MINCKWITZ, G, DAN COSTA, S, EIERMANN, W, BLOHMER, J.-U, TULUSAN, A. H, JACKISCH, C, KAUFMANN, M

“…To assess the toxicity and efficacy of preoperative chemotherapy with doxorubicin and docetaxel in patients with primary operable breast cancer. Forty-two…”
Get full text